Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$3.7M
Filings
69
Firms Hired
1
Active Period
2010–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Advocated for antimicrobial resistance legislation. Supported the Medicare Coverage Innovation Pathway at CMS and expressed concerns with its withdrawal Submitted comments to FDA on cell and gene therapy early-stage clinical trials Hosted a legislative roundtable with Rep. Garcia to discuss the life science industry Hosted a legislative roundtable with Rep. Obernolte to discuss the life science industry Hosted an executive roundtable with CDRH to discuss the digital health center of excellence Hosted an executive roundtable with OSTP to discuss health care and life science priorities and initiatives
Client expense: $45,000 · Firm income: —
Matched citations: HR3
Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Submitted comments on the Cures 2.0 draft legislation Advocated for antimicrobial resistance legislation
Client expense: $45,000 · Firm income: —
Matched citations: HR3
Advocated against HR3 via individual meetings with congressional offices and hosting a webinar for legislative staff on HR3 and patient access.
Client expense: $45,000 · Firm income: —
Matched citations: HR3
Provided information on industry's response regarding the covid-19 pandemic Advocated against international reference pricing policies, including most favored nation and HR3 Presented new data from Vital Transformation on the impact of HR3 Hosted a webinar on international reference pricing Hosted a roundtable with Rep. Sara Jacobs Advocated in favor of CMS's MCIT coverage pathway for devices designated as breakthrough by the FDA Advocated against CMS's rule to waive protections for protected classes of drugs
Client expense: $45,000 · Firm income: —
Matched citations: HR3
Advocated against HR3, the Lower Drug Costs Now Act of 2019, because of the negative impact it would have on innovation. Co-commissioned a joint report by Vital Transformation on the impact of HR3 on California.
Client expense: $35,000 · Firm income: —
Matched citations: HR3
Advocated against HR3, the Lower Drug Costs Now Act of 2019, because of the negative impact it would have on innovation. Hosted a congressional briefing on Precision Medicine. Hosted a legislative roundtable with Rep. Eric Swalwell.
Client expense: $50,000 · Firm income: —
Matched citations: HR3
Asked to vote for HR6, the 21st Century Cures Act.
Client expense: $40,000 · Firm income: —
Matched citations: HR6
Raised concerns with H.R.9, the Innovation Act, and asked Members to oppose the bill. Advocated for a Hatch-Waxman/BPCIA exemption from IPR proceedings.
Client expense: $40,000 · Firm income: —
Matched citations: H.R.9
Urged Members to support H.R.160, the bill to a repeal the medical device tax. Urged Members to support H.R.880, the bill to make the R&D tax credit permanent.
Client expense: $45,000 · Firm income: —
Matched citations: H.R.160
Targeting Rogue and Opaque Letters Act of 2015
2015 · second_quarter · Firm: BIOCOM
Raised concerns with H.R.9, the Innovation Act and asked Members to oppose the bill. Expressed support for S.632, the Strong Patents Act and H.R.2045, the Trol Act.
Client expense: $45,000 · Firm income: —
Matched citations: H.R.2045
Discussed legislative proposals in the 21st Century Cures Initiative and asked Members to support H.R.6. Submitted comments to the Energy & Commerce Committee regarding 21st Century Cures. Submitted comments to House and Senate committees on patient remote monitoring . Co-hosted Congressional briefings on FDA user fee programs in the House and Senate.
Client expense: $45,000 · Firm income: —
Matched citations: H.R.6
American Research and Competitiveness Act of 2015
2015 · second_quarter · Firm: BIOCOM
Urged Members to support H.R.160, the bill to a repeal the medical device tax. Urged Members to support H.R.880, the bill to make the R&D tax credit permanent.
Client expense: $45,000 · Firm income: —
Matched citations: H.R.880
Raised concerns with H.R.9, the Innovation Act and asked Members to oppose the bill. Expressed support for S.632, the Strong Patents Act and H.R.2045, the Trol Act.
Client expense: $45,000 · Firm income: —
Matched citations: H.R.9
Raised concerns with H.R.9, the Innovation Act and asked Members to oppose the bill. Expressed support for S.632, the Strong Patents Act and H.R.2045, the Trol Act.
Client expense: $45,000 · Firm income: —
Matched citations: S.632
Raised concerns with H.R.9, the Innovation Act. Expressed support for S.632, the Strong Patents Act and for reintroduction of the Trol Act.
Client expense: $44,000 · Firm income: —
Matched citations: H.R.9
Raised concerns with H.R.9, the Innovation Act. Expressed support for S.632, the Strong Patents Act and for reintroduction of the Trol Act.
Client expense: $44,000 · Firm income: —
Matched citations: S.632
Voiced support for track & trace provisions of H.R. 3204 Asked to oppose cuts to Medicare Part B and D
Client expense: $41,564 · Firm income: —
Matched citations: H.R. 3204
Federal Agriculture Reform and Risk Management Act of 2012
2012 · fourth_quarter · Firm: BIOCOM
- Farm Bill H.R. 6083.
Client expense: $24,079 · Firm income: —
Matched citations: H.R. 6083
Fannie Mae and Freddie Mac Transparency Act of 2011
2012 · third_quarter · Firm: BIOCOM
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463
Client expense: $40,217 · Firm income: —
Matched citations: HR 463
Fannie Mae and Freddie Mac Transparency Act of 2011
2012 · second_quarter · Firm: BIOCOM
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced support for HR4953, the Qualifying renewable chemical production tax credit Act of 2012
Client expense: $52,000 · Firm income: —
Matched citations: HR 463
Qualifying Renewable Chemical Production Tax Credit Act of 2012
2012 · second_quarter · Firm: BIOCOM
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced support for HR4953, the Qualifying renewable chemical production tax credit Act of 2012
Client expense: $52,000 · Firm income: —
Matched citations: HR4953
Fannie Mae and Freddie Mac Transparency Act of 2011
2012 · second_quarter · Firm: BIOCOM
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced Support for HR4953, the Qualifying Renewable Chemical Production Tax Credit Act of 2012
Client expense: $52,000 · Firm income: —
Matched citations: HR 463
Qualifying Renewable Chemical Production Tax Credit Act of 2012
2012 · second_quarter · Firm: BIOCOM
- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463 - Voiced Support for HR4953, the Qualifying Renewable Chemical Production Tax Credit Act of 2012
Client expense: $52,000 · Firm income: —
Matched citations: HR4953
Regenerative Medicine Promotion Act of 2011
2012 · first_quarter · Firm: BIOCOM
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
Client expense: $52,000 · Firm income: —
Matched citations: HR 1862
Generating Antibiotic Incentives Now Act of 2011
2012 · first_quarter · Firm: BIOCOM
Voiced support for HR 2182, The Generativng Antibiotic Incentives Now ("GAIN") Act. The legislation provides incentives for the development of infectious disease products. Voiced opposition to HR 3699, the Research Works Act. Voiced support for HR 1862, the Regenerative Medicine Promotion Act. The legislation encourages private investment in R&D, and it enables accelerated approval for regenerative medicine products. Voiced opposition to HR 3433, the Grant Reform and New Transparency Act of 2011 (GRANT ACT). The legislation requires certain standards in the award of federal grants, and for other purposes. Voiced opposition over the IPAB. Voiced opposition over proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides onology products for administration in physicians offices.
Client expense: $52,000 · Firm income: —
Matched citations: HR 2182
Source: Senate LDA